AbClon Inc. (KOSDAQ:174900)
South Korea · Delayed Price · Currency is KRW 62,400
+3,000 (5.05%)
Feb 9, 2026, 9:29 AM KST
AbClon Revenue
AbClon had revenue of 1.57B KRW in the quarter ending September 30, 2025, with 96.27% growth. This brings the company's revenue in the last twelve months to 3.80B, up 73.29% year-over-year. In the year 2024, AbClon had annual revenue of 2.34B, down -18.67%.
Revenue (ttm)
3.80B
Revenue Growth
+73.29%
P/S Ratio
311.40
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.18T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.34B | -537.21M | -18.67% |
| Dec 31, 2023 | 2.88B | -527.18M | -15.49% |
| Dec 31, 2022 | 3.40B | 386.15M | 12.79% |
| Dec 31, 2021 | 3.02B | 246.87M | 8.91% |
| Dec 31, 2020 | 2.77B | -11.60B | -80.72% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HansBiomed | 89.78B |
| Aimed Bio | 29.65B |
| ROKIT Healthcare | 20.33B |
| JS Link | 16.14B |
| AprilBio | 8.97B |
| Qurient | 8.28B |
| IntoCell | 1.68B |
| ToolGen | 1.07B |